Last updated: October 27, 2026
VISKEN, the original brand for pindolol, is a mature antihypertensive with limited commercial value. U.S. sales have been displaced by generic pindolol and newer beta blockers, while the branded product has no meaningful remaining exclusivity. The drug is not a biologic, has no biosimilar exposure, and has limited strategic value for large pharmaceutical companies. Public filings do not disclose standalone VISKEN revenue, so its financial trajectory must be assessed through market access, generic competition, prescribing guidelines, and portfolio strategy.
What is VISKEN and how is pindolol used?
VISKEN contains pindolol, a nonselective beta-adrenergic blocker with intrinsic sympathomimetic activity. The FDA-approved U.S. indication is hypertension, either alone or with another antihypertensive agent. Historical labeling identifies tablet strengths of 5 mg, 10 mg, and 15 mg.[1]
Pindolol differs from commonly used beta blockers such as metoprolol, atenolol, carvedilol, and bisoprolol because it partially stimulates beta receptors while blocking stronger catecholamine effects. This pharmacology can reduce resting bradycardia relative to some other beta blockers, but it has not supported broad modern adoption.
The commercial product is generally categorized as:
| Attribute |
VISKEN / pindolol |
| Active ingredient |
Pindolol |
| Drug class |
Nonselective beta blocker |
| Intrinsic activity |
Yes |
| Original indication |
Hypertension |
| Dosage form |
Immediate-release oral tablet |
| U.S. reference product |
VISKEN |
| FDA approval era |
1970s |
| Biologic |
No |
| Biosimilar pathway |
Not applicable |
| Current market position |
Mature generic product |
When did VISKEN lose exclusivity?
VISKEN lost meaningful U.S. market exclusivity decades ago. The product was approved in the 1970s, and generic pindolol products have long been available. Any original patent protection and regulatory exclusivity associated with the reference product have expired.
The FDA Orange Book does not present VISKEN as a product with a commercially material active patent estate. The economic protection for the original brand therefore comes from neither patent enforcement nor regulatory exclusivity. It depends on residual brand loyalty, supply continuity, prescriber familiarity, or niche distribution.
What is the Orange Book status of VISKEN?
VISKEN is an old small-molecule reference product. The Orange Book framework is relevant to the product because generic applicants can rely on an abbreviated new drug application pathway, but the product does not have the type of active listed-patent profile associated with newer branded drugs.
The practical consequences are:
- No meaningful remaining brand patent barrier.
- No 30-month-stay risk from a current Paragraph IV campaign of commercial importance.
- No pediatric exclusivity or new chemical entity exclusivity remaining.
- Generic substitution is legally and commercially established.
- Any manufacturer can compete subject to FDA approval, supply economics, and market availability.
FDA approval of a generic pindolol product does not require the generic company to reproduce the VISKEN brand. It requires pharmaceutical equivalence and bioequivalence under the applicable abbreviated approval pathway.[2]
How many patents cover VISKEN and pindolol?
No active U.S. patent estate with material commercial relevance is apparent for VISKEN as an approved legacy product. The original composition, formulation, and use patents associated with the product’s development period have expired.
There is no current patent-based barrier comparable to the estates surrounding newer cardiovascular products. Any newly filed patent would need to cover a genuinely novel formulation, use, manufacturing process, or delivery system. A patent directed only to the old pindolol molecule would not provide new enforceable exclusivity because the active ingredient has been known and marketed for decades.
What formulations are protected by VISKEN patents?
The commercially relevant dosage form is the conventional immediate-release tablet. There is no publicly important modern extended-release, transdermal, implantable, or specialty-delivery patent platform associated with VISKEN.
Potential formulation opportunities would face several limits:
- Pindolol is an established active ingredient.
- The hypertension market has multiple low-cost alternatives.
- A new formulation would need to produce a clinically or commercially meaningful advantage.
- Generic substitution and payer price pressure would limit premium pricing.
- A formulation patent would not automatically protect the broader pindolol market.
The absence of a differentiated delivery system has kept pindolol commercially exposed to commodity competition.
What is the FDA regulatory status of VISKEN?
VISKEN is an FDA-approved small-molecule prescription drug. Its primary regulatory importance is historical rather than innovative. Pindolol remains recognized as an approved active ingredient, and generic products may be marketed under abbreviated approval procedures.
FDA labeling warns against abrupt withdrawal in patients with coronary artery disease and describes contraindications and precautions relevant to beta-blocker therapy.[1] Current treatment decisions are influenced by the broader hypertension evidence base and by the availability of agents with stronger outcome data.
The 2017 American College of Cardiology and American Heart Association hypertension guideline does not place beta blockers, including pindolol, among preferred first-line treatments for uncomplicated hypertension. Preferred initial classes are thiazide diuretics, calcium-channel blockers, and angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.[3]
This guideline position reduces the addressable market for pindolol unless a patient has a specific clinical reason for beta-blocker therapy.
How does VISKEN compare with competing beta blockers?
Pindolol competes in a crowded and largely generic beta-blocker market. The principal alternatives have stronger current prescribing positions, broader clinical familiarity, or more established roles in heart failure, ischemic heart disease, arrhythmia, or post-myocardial-infarction care.
| Drug |
Core commercial position |
Relative market pressure on pindolol |
| Metoprolol |
Widely used in hypertension, angina, arrhythmia, and heart failure |
Very high |
| Atenolol |
Low-cost legacy beta blocker |
High |
| Propranolol |
Broad cardiovascular and neurologic uses |
High |
| Carvedilol |
Heart failure and cardiovascular disease |
High |
| Bisoprolol |
Hypertension and heart failure markets |
High |
| Nebivolol |
More differentiated hypertension positioning |
Moderate to high |
| Pindolol |
Niche legacy beta blocker |
Limited |
Pindolol’s intrinsic sympathomimetic activity is a technical differentiator, but it has not translated into a durable commercial advantage. Prescribers generally prioritize evidence-based cardiovascular outcomes, tolerability, dosing convenience, formulary access, and cost.
What is the financial trajectory for VISKEN?
VISKEN’s financial trajectory follows the standard pattern for an old genericized cardiovascular product:
- Initial branded growth after launch.
- Loss of exclusivity.
- Rapid price and market-share erosion after generic entry.
- Long-term survival through low-cost generic supply.
- Declining strategic value as prescribing shifts to competing agents.
No major pharmaceutical company publicly reports standalone VISKEN revenue in current annual filings. Companies generally aggregate mature generic cardiovascular products within broader pharmaceutical or generic portfolios. As a result, a precise current VISKEN revenue figure cannot be derived from public issuer disclosures.
The product’s economics are likely characterized by:
- Low average selling prices.
- Small absolute revenue per prescription.
- High sensitivity to manufacturing interruptions.
- Limited marketing expenditure.
- Low return on incremental clinical development.
- Revenue concentration among a small number of generic suppliers when competitors exit.
A legacy product can still generate recurring revenue if it has stable demand and few manufacturers. That revenue is usually a portfolio-maintenance asset rather than a growth asset. Margin performance depends more on manufacturing cost and supply discipline than on brand equity.
Does VISKEN generate material revenue for Novartis?
Novartis has not historically disclosed VISKEN revenue as a separate material product line in its public financial reporting. The absence of a product-level disclosure indicates that VISKEN is not financially material to the company’s consolidated results, rather than proving that the product generates no revenue.
VISKEN’s commercial value to a portfolio owner would be limited to residual demand, established regulatory status, and the ability to manufacture or source the tablets economically. It would not be expected to influence group revenue growth, valuation, or major capital-allocation decisions.
What generic entry risks exist for VISKEN?
Generic entry risk is effectively realized rather than prospective. Pindolol has been genericized for many years. The relevant business risks are generic competition, market exit, and supply disruption.
Which companies are challenging VISKEN?
There is no commercially significant current Paragraph IV challenge required to displace VISKEN. Generic pindolol manufacturers have already entered the market through the established abbreviated approval pathway.
The competitive field may change when individual suppliers discontinue products. In a small mature market, the larger threat can be supply consolidation rather than new entry. A product with several approved manufacturers may still experience shortages if only one or two remain active in practice.
What patent litigation affects VISKEN?
No major current patent litigation is associated with VISKEN or pindolol as a commercially important branded product. The product’s key patent disputes would have occurred during the original development and genericization periods, not during the current mature-market phase.
The litigation profile is therefore materially different from newer drugs with:
- Multiple Orange Book-listed patents.
- Paragraph IV notices.
- Patent-term extensions.
- Formulation or device patents.
- Settlement agreements delaying generic launch.
- Authorized-generic strategies.
No active settlement agreement is central to the current VISKEN market structure.
Is there biosimilar risk for VISKEN?
Biosimilar risk does not apply. Pindolol is a chemically synthesized small molecule, not a biologic. Competition occurs through generic-drug approval pathways, not through the FDA biosimilar pathway under the Public Health Service Act.
The relevant substitution mechanism is generic interchangeability under state pharmacy laws and payer formulary rules. That mechanism has already removed most of the original brand premium.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are modest but not negligible. Pindolol tablets require controlled active-ingredient sourcing, validated tableting processes, quality testing, packaging, and FDA-compliant manufacturing. These requirements create operational barriers, but they do not create durable market exclusivity.
The principal residual barriers are:
- Active pharmaceutical ingredient availability.
- Low market volume relative to fixed manufacturing costs.
- FDA inspection and compliance requirements.
- Product discontinuation decisions.
- Inventory economics.
- Limited commercial incentive to maintain redundant capacity.
Intellectual-property barriers are weak. Manufacturing know-how can support cost advantages, but it is unlikely to block a capable generic competitor.
What is the outlook for the VISKEN market?
The outlook is stable to declining in volume, with a low probability of material price recovery. Pindolol may retain a small niche among patients who respond to or tolerate its pharmacologic profile, but the product is unlikely to regain broad hypertension-market relevance.
The most probable commercial scenarios are:
| Scenario |
Probability assessment |
Market effect |
| Continued low-volume generic supply |
Most likely |
Stable niche revenue |
| Further supplier consolidation |
Material risk |
Greater shortage and pricing volatility |
| Brand revival |
Low |
Limited payer and prescriber support |
| New formulation investment |
Low |
Weak return on investment |
| Broad clinical re-adoption |
Very low |
Guideline and competition barriers |
| Complete commercial withdrawal |
Possible over time |
Patients shift to alternatives |
A buyer evaluating a pindolol asset would likely value it on near-term cash flow, supply reliability, regulatory maintenance cost, and manufacturing margin. Patent upside would contribute little or nothing to valuation.
How does VISKEN compare with newer cardiovascular drug assets?
VISKEN has low development risk because its active ingredient and clinical use are established. It has high commercial maturity risk because the market is generic and crowded. Newer cardiovascular assets may carry greater clinical and regulatory risk but offer stronger pricing power and growth potential.
| Value driver |
VISKEN |
New cardiovascular asset |
| Patent life |
Essentially exhausted |
Potentially significant |
| Regulatory risk |
Low |
Medium to high |
| Pricing power |
Very low |
Moderate to high |
| Clinical differentiation |
Limited |
Potentially strong |
| Generic substitution |
Established |
May be delayed |
| Revenue growth |
Unlikely |
Possible |
| Litigation exposure |
Low |
Potentially high |
| Manufacturing complexity |
Low to moderate |
Variable |
| Strategic value |
Portfolio maintenance |
Growth or platform asset |
Key Takeaways
- VISKEN is the legacy brand for pindolol, an established nonselective beta blocker with intrinsic sympathomimetic activity.
- FDA approval dates to the 1970s, and meaningful U.S. exclusivity has expired.
- No active patent estate appears to provide material commercial protection.
- Generic pindolol has already replaced the branded market in practical terms.
- Paragraph IV, biosimilar, and current patent-settlement risks are not central to the product.
- Standalone VISKEN revenue is not disclosed by major pharmaceutical companies.
- Financial value is limited to residual generic demand, manufacturing margin, and supply continuity.
- Pindolol faces strong competition from metoprolol, atenolol, propranolol, carvedilol, bisoprolol, and other beta blockers.
- Modern hypertension guidelines reduce the product’s first-line treatment relevance.
- The main forward risk is supplier consolidation or discontinuation, not patent expiry.
FAQs About VISKEN and Pindolol
Is VISKEN still available in the United States?
Generic pindolol availability is more commercially relevant than branded VISKEN availability. Product status can vary by manufacturer, distributor, and dosage strength.
Is pindolol a first-line hypertension medicine?
Generally, no. Current hypertension guidelines favor thiazide diuretics, calcium-channel blockers, ACE inhibitors, and angiotensin-receptor blockers for many patients without a specific beta-blocker indication.[3]
Does VISKEN have an authorized generic?
An authorized-generic determination depends on the relevant product owner and current distribution arrangements. The existence of generic pindolol does not establish that an authorized generic VISKEN product is actively marketed.
Can a new pindolol formulation obtain patent protection?
A novel formulation may be patentable if it satisfies statutory novelty, non-obviousness, and written-description requirements. Such protection would cover the claimed formulation, not the old pindolol molecule broadly.
Is VISKEN commercially attractive for pharmaceutical licensing?
Only as a low-growth mature-product opportunity. Licensing value would depend on manufacturing cost, supply continuity, geographic rights, product availability, and the seller’s ability to transfer regulatory assets. Patent-based upside is limited.
References
- U.S. Food and Drug Administration. (2009). Visken (pindolol) tablets prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
